Company Overview

Update
Founded:
2007
Founders:
Chris Marich, Taneli Jouhikainen, Rob Neville
Headquarters:
Austin, TX
Funding:
$31.50M
Categories:
Biotechnology

Savara Pharmaceuticals develops NanoCluster formulation technology-based pulmonary drug delivery solutions.

Description

Update

Savara Pharmaceuticals develops next generation pulmonary drug delivery solutions using its NanoCluster formulation technology. Dry powder and nebulizer-based medicines are formulated directly from active drug ingredients, requiring no carrier particles and little or no excipients. The aerodynamics of NanoCluster formulations are fully customizable from one to seven microns enabling high drug concentrations at specific regions of the lung, independent of the rate or depth of breath. Savara expects that NanoCluster’s unique features will produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience. Savara’s NanoCluster technology is currently available for evaluation and licensing.

Current Team (8)

Update

Board Members and Advisors (2)

Update

Funding Rounds (6) - $31.50M

Update

Investors (4)

Update

Offices/Locations (1)

Update
  • Office

    3925 West Braker Lane

    Austin, TX 78759

    USA

Images (1)

Update
  • 16ed98dab071449c63cb3ca947a88c20